VentriPoint Diagnostics (CVE:VPT) Stock Price Up 16.7% – Time to Buy?

Shares of VentriPoint Diagnostics Ltd. (CVE:VPT) traded up 16.7% during trading on Wednesday . The company traded as high as C$0.16 and last traded at C$0.14. 771,459 shares traded hands during mid-day trading, an increase of 362% from the average session volume of 167,018 shares. The stock had previously closed at C$0.12.

VentriPoint Diagnostics Stock Up 16.7%

The company has a debt-to-equity ratio of -58.56, a current ratio of 0.28 and a quick ratio of 6.67. The stock has a market cap of C$23.48 million, a PE ratio of -4.67 and a beta of -0.41. The business has a fifty day moving average of C$0.10 and a 200-day moving average of C$0.11.

About VentriPoint Diagnostics

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.